Country access

Can I access it where I live?

Approval, local supply, payment and research participation are different questions. Choose a country to see what the sources establish for each one.

7 country–item profiles have sourced facts so far. Search any item; unchecked fields are labeled explicitly. Unknown does not mean unavailable.

Find an item · How to read these entries · Australian trials

Find country-specific access information

Country or regulatory areaSearch every itemShow

Your selection stays in the link. We do not use your location.

Choose a country to see its access facts and gaps. You can search every item before choosing. If your country is not listed, the item’s evidence page may offer context, but country access has not been established by this index.

212 of 212 items · showing 1–20

Abatacept (CTLA4-Ig)Prevention therapies · Choose a country to check access

Read the evidence, safety discussion and full sources →

Select a country above to distinguish approval, supply, funding and research access.

Report an access correction

Abbott Libre DuoCGMs · Choose a country to check access

Read the evidence, safety discussion and full sources →

Select a country above to distinguish approval, supply, funding and research access.

Report an access correction

Abbott LingoCGMs · Choose a country to check access

Read the evidence, safety discussion and full sources →

Select a country above to distinguish approval, supply, funding and research access.

Report an access correction

Accu-Chek SmartGuideCGMs · Choose a country to check access

Read the evidence, safety discussion and full sources →

Select a country above to distinguish approval, supply, funding and research access.

Report an access correction

Accu-Chek Solo micropumpPumps · Choose a country to check access

Read the evidence, safety discussion and full sources →

Select a country above to distinguish approval, supply, funding and research access.

Report an access correction

AIDANET fully closed-loop algorithmAID systems · Choose a country to check access

Read the evidence, safety discussion and full sources →

Select a country above to distinguish approval, supply, funding and research access.

Report an access correction

Ain Shams adipose-derived insulin-producing cellsCell replacement · Choose a country to check access

Read the evidence, safety discussion and full sources →

Select a country above to distinguish approval, supply, funding and research access.

Report an access correction

Alefacept (CD2 memory T-cell targeting)Prevention therapies · Choose a country to check access

Read the evidence, safety discussion and full sources →

Select a country above to distinguish approval, supply, funding and research access.

Report an access correction

Allogeneic CD7-CAR-T (RD13-02)Immunotherapies · Choose a country to check access

Read the evidence, safety discussion and full sources →

Select a country above to distinguish approval, supply, funding and research access.

Report an access correction

AndroidAPSDIY & open-source loops · Choose a country to check access

Read the evidence, safety discussion and full sources →

Select a country above to distinguish approval, supply, funding and research access.

Report an access correction

Anti-IL-21 antibody + liraglutideImmunotherapies · Choose a country to check access

Read the evidence, safety discussion and full sources →

Select a country above to distinguish approval, supply, funding and research access.

Report an access correction

ASITI-201 (proinsulin peptide / calcitriol liposomes)Immunotherapies · Choose a country to check access

Read the evidence, safety discussion and full sources →

Select a country above to distinguish approval, supply, funding and research access.

Report an access correction

ASK (Autoimmunity Screening for Kids)Screening & early detection · Choose a country to check access

Read the evidence, safety discussion and full sources →

Select a country above to distinguish approval, supply, funding and research access.

Report an access correction

Aspect Biosystems bioprinted islet tissue (ex-Novo Nordisk platform)Gene & combination approaches · Choose a country to check access

Read the evidence, safety discussion and full sources →

Select a country above to distinguish approval, supply, funding and research access.

Report an access correction

AT247 ultra-rapid insulinInsulins · Choose a country to check access

Read the evidence, safety discussion and full sources →

Select a country above to distinguish approval, supply, funding and research access.

Report an access correction

AT278 (U500 ultra-rapid insulin aspart)Insulins · Choose a country to check access

Read the evidence, safety discussion and full sources →

Select a country above to distinguish approval, supply, funding and research access.

Report an access correction

Australian T1D National Screening PilotScreening & early detection · Choose a country to check access

Read the evidence, safety discussion and full sources →

Select a country above to distinguish approval, supply, funding and research access.

Report an access correction

Autologous CD6-CAR regulatory T cellsImmunotherapies · Choose a country to check access

Read the evidence, safety discussion and full sources →

Select a country above to distinguish approval, supply, funding and research access.

Report an access correction

Autologous polyclonal Treg therapy (T-Rex program)Immunotherapies · Choose a country to check access

Read the evidence, safety discussion and full sources →

Select a country above to distinguish approval, supply, funding and research access.

Report an access correction

AVAnT1A (early COVID-19 vaccination, GPPAD primary prevention)Prevention therapies · Choose a country to check access

Read the evidence, safety discussion and full sources →

Select a country above to distinguish approval, supply, funding and research access.

Report an access correction

How to read these entries

Each fact has its own source and check date. “Checked” describes that access statement, not a new review of all clinical evidence. Source dates may be older; an official decision or published supply pathway is not a live stock, coverage or appointment check.

Approval & indication: the regulator’s permitted use and population. Device clearance and medicine approval are identified separately.
Launch & supply: a documented route to obtain the product. Availability at a particular pharmacy or clinic may differ.
Funding & reimbursement: a dated payer decision, policy or support program. Eligibility and individual costs still need confirmation.
Research access: a registered study and its dated recruitment information. Study listing does not establish treatment effectiveness or routine access.

Manufacturer sources describe the manufacturer’s own pathway. General insurer policies are labeled as such, rather than treated as product-specific coverage. Existing region tags on the site remain record context and are not converted into country access facts.

These are AI-assisted editorial checks, with source-specific limits. Recheck the linked source with your clinic, pharmacy, payer or trial site when making an access decision. Updates are not continuous and no next review date is guaranteed. Send a correction with a primary source.

Sourced access profiles

Enable JavaScript to filter. All sourced profiles and the complete item index remain available below.

Teplizumab (Tzield) — Australia

Read the evidence and safety discussion

Approval & indication: TGA registered Tzield on 21 May 2026 to delay stage 3 type 1 diabetes in adults and children aged 8 years and older with stage 2 disease. This indication differs from the US label. TGA: Tzield Australian prescription medicine decision (regulator; checked 2026-09-17; source dated 2026-06-04).
Launch & supply: Not yet checked.
Funding & reimbursement: At its July 2026 meeting, PBAC did not recommend the requested PBS listing for delaying stage 3 disease in people aged 8 years and older with stage 2 disease. This is the dated decision checked here; a later PBS listing and private costs have not been established by this check. PBAC July 2026 meeting outcomes — teplizumab (payer; checked 2026-09-17; exact source date not recorded).
Research access: Not yet checked.

Teplizumab (Tzield) — United States

Read the evidence and safety discussion

Approval & indication: The June 2026 US label covers delaying stage 3 disease from age 1 year in stage 2 T1D. It also includes an accelerated approval to delay loss of insulin production in ages 8–17 with recently diagnosed stage 3 T1D (within 8 weeks). Continued approval for the stage 3 indication depends on confirmatory evidence. Read the full label for eligibility and safety requirements. Tzield US prescribing information — revised June 2026 (regulator-approved label; checked 2026-09-17; exact source date not recorded).
Launch & supply: Sanofi describes specialty-pharmacy or buy-and-bill procurement and help locating an infusion site through TZIELD COMPASS. This establishes a manufacturer access pathway; local stock, clinical suitability and appointment availability were not confirmed. Sanofi: TZIELD COMPASS procurement and site support (manufacturer; checked 2026-09-17; exact source date not recorded).
Funding & reimbursement: The manufacturer describes copay support for eligible commercially insured patients, with government-funded insurance excluded. A support program is not confirmation of an individual insurance decision or coverage of every infusion-related cost. Sanofi: Tzield financial support and program conditions (manufacturer; checked 2026-09-17; exact source date not recorded).
Research access: Not yet checked.

Teplizumab (Tzield) — United Kingdom

Read the evidence and safety discussion

Approval & indication: MHRA approved teplizumab on 14 August 2025 to delay stage 3 type 1 diabetes in adults and children aged 8 years and older with stage 2 disease. MHRA: teplizumab approval (regulator; checked 2026-09-17; source dated 2025-08-14).
Launch & supply: Not yet checked.
Funding & reimbursement: England: NICE TA1176 recommends teplizumab within its eligibility conditions. NHS England must make funding available within 90 days of publication on 9 July 2026 when the treatment is clinically appropriate. This implementation window was still running on the check date; local service readiness and funding in Scotland, Wales and Northern Ireland were not checked here. NICE TA1176: implementation and NHS funding duty (payer; checked 2026-09-17; source dated 2026-07-09).
Research access: Not yet checked.

Teplizumab (Tzield) — European Union (regulatory area)

Read the evidence and safety discussion

Approval & indication: Teizeild received EU-wide marketing authorization on 8 January 2026 to delay stage 3 T1D in adults and children aged 8 years and older with stage 2 disease. EU authorization does not establish launch or reimbursement in a particular member country. EMA: Teizeild European public assessment report (regulator; checked 2026-09-17; exact source date not recorded).
Launch & supply: Not yet checked.
Funding & reimbursement: Not yet checked.
Research access: Not yet checked.

Dexcom G7 — Australia

Read the evidence and safety discussion

Dexcom G7 — United States

Read the evidence and safety discussion

Approval & indication: FDA cleared the prescription Dexcom G7 CGM for diabetes management in people aged 2 years and older. This entry concerns the 10-day G7 model; G7 15 Day is a separate product with its own label. FDA: Dexcom G7 510(k) clearance K213919 (regulator; checked 2026-09-17; source dated 2022-12-07).
Launch & supply: Dexcom describes obtaining G7 by prescription through a local pharmacy when pharmacy benefits apply, or through a designated distributor. The route depends on insurance; local stock was not checked. Dexcom: pharmacy and distributor availability (manufacturer; checked 2026-09-17; exact source date not recorded).
Funding & reimbursement: General CGM policy: Medicare Part B may cover a prescribed CGM for eligible people with diabetes who use insulin or meet the problematic-hypoglycemia criteria, with other provider and training requirements. This is not a G7-specific coverage authorization; private insurance decisions were not checked. Medicare: continuous glucose monitor coverage (payer; checked 2026-09-17; exact source date not recorded).
Research access: Not yet checked.

Baricitinib (JAK1/2 inhibitor) — Australia

Read the evidence and safety discussion

Approval & indication: Not yet checked.
Launch & supply: Not yet checked.
Funding & reimbursement: Not yet checked.
Research access: BARICADE-PRESERVE (NCT07222332) is a phase 3 study in recently diagnosed T1D. The registry update posted 4 September 2026 lists 10 Australian sites: 8 recruiting and 2 not yet recruiting. These are registered site statuses, not confirmed vacancies; eligibility and current recruitment require contact with the study. This is investigational access, not evidence of routine T1D treatment availability. ClinicalTrials.gov: BARICADE-PRESERVE site status (trial registry; checked 2026-09-17; source dated 2026-09-04).

All items